Literature DB >> 27021

[On the binding of cyclophosphamide and cyclophosphamide-metabolites to serum-albumin (author's transl)].

G Voelcker, H P Giera, L Jäger, H J Hohorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 27021     DOI： 10.1007/BF00284020

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN： 0084-5353


× No keyword cloud information.
  18 in total

1.  Studies on cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds.

Authors:  A Takamizawa; S Matsumoto; T Iwata; Y Tochino; K Katagiri; K Yamaguchi
Journal:  J Med Chem       Date:  1975-04       Impact factor: 7.446

2.  The relation of free sulfhydryl groups to chromatographic heterogeneity and polymerization of bovine plasma albumin.

Authors:  R W HARTLEY; E A PETERSON; H A SOBER
Journal:  Biochemistry       Date:  1962-01       Impact factor: 3.162

3.  [Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents].

Authors:  N BROCK
Journal:  Arzneimittelforschung       Date:  1958-01

4.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

5.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

6.  Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.

Authors:  A Takamizawa; S Matsumoto; T Iwata; Y Tochino; K Katagiri
Journal:  J Med Chem       Date:  1974-11       Impact factor: 7.446

7.  Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

Authors:  U Draeger; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

8.  Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.

Authors:  G Peter; T Wagner; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

10.  The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.

Authors:  H J Hohorst; U Draeger; G Peter; G Voelcker
Journal:  Cancer Treat Rep       Date:  1976-04
View more
  5 in total

1.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].

Authors:  T Wagner; D Heydrich; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1980-01       Impact factor: 4.553

3.  Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy.

Authors:  P Coassolo; M Valentin; M Bourdeaux; C Briand
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

4.  Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides.

Authors:  G Peter; H J Hohorst
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.